Patients who progressed ‐ at 2 years · people with multiple sclerosis
Glatiramer acetate showed no clear difference in patients who progressed ‐ at 2 years compared with placebo; GRADE not reported.
2 findings from 1 review
Change in disability score at the end of · people with multiple sclerosis
2 findings from 1 review
Relapse · people with multiple sclerosis
1 finding from 1 review
Mean number of relapses ‐ at 2 years of · people with multiple sclerosis
1 finding from 1 review
Intervention not reported
Glatiramer acetate (Direct evidence; 3 RCsT; 1014 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention probably leads to lower glatiramer acetate (Direct evidence; 3 RCsT; 1014 participants) (moderate certainty).
1 finding from 1 review
RR 0.84 [0.76, 0.93]
3 participants
Moderate
Intervention not reported
Glatiramer acetate (Direct evidence; 3 RCTs; 1014 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
It is very uncertain whether the intervention changes glatiramer acetate (Direct evidence; 3 RCTs; 1014 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Glatiramer acetate (Direct evidence; 2 RCTs; 1454 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
The intervention may leads to lower glatiramer acetate (Direct evidence; 2 RCTs; 1454 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Glatiramer acetate (Direct evidence; 4 RCTs; 2419 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention probably leads to higher glatiramer acetate (Direct evidence; 4 RCTs; 2419 participants) (moderate certainty).
1 finding from 1 review
Intervention not reported
Glatiramer acetate (Direct evidence; 3 RCTs; 2371 participants) · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…
The intervention showed no clear difference in glatiramer acetate (Direct evidence; 3 RCTs; 2371 participants) (low certainty).
1 finding from 1 review
Interferons or glatiramer acetate · relapsing multiple sclerosis
It is very uncertain whether rituximab as 'switching' changes interferons or glatiramer acetate compared with other disease‐modifying treatments (very low certainty).
1 finding from 1 review
HR 0.86 [0.52, 1.42]
853 participants
Very low
Interferon beta or glatiramer acetate · relapsing multiple sclerosis
Rituximab as 'switching' probably leads to higher interferon beta or glatiramer acetate compared with other disease‐modifying treatments (moderate certainty).
2 findings from 1 review
OR 1.71 [1.11, 2.62]
5477 participants
Moderate
HR 0.14 [0.05, 0.39]
335 participants
Moderate
Intervention not reported
Glatiramer acetate
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse · patients with relapsing‐remitting multiple sclerosis
Interferons showed no clear difference in number of participants with relapse Risk ratio (M‐H, random, 95% CI) compared with glatiramer acetate (moderate certainty).
1 finding from 1 review
Number of participants with confirmed progression Risk ratio (M‐H, random, 95% CI) · patients with relapsing‐remitting multiple sclerosis
Interferons showed no clear difference in number of participants with confirmed progression Risk ratio (M‐H,… compared with glatiramer acetate (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with relapsing‐remitting multiple sclerosis
Interferons showed no clear difference in number of participants who dropped out for AEs Risk ratio (M‐H,… compared with glatiramer acetate (low certainty).
1 finding from 1 review
Mean number of active T2 lesions Mean difference (IV, random, 95% CI) · patients with relapsing‐remitting multiple sclerosis
1 finding from 1 review
Mean number of new enhancing lesions Mean difference (IV, random, 95% CI) · patients with relapsing‐remitting multiple sclerosis
1 finding from 1 review
Mean change in total T2‐hyperintense lesion load Mean difference (IV, random, 95% CI) · patients with relapsing‐remitting multiple sclerosis
1 finding from 1 review
Mean change in total T1‐hypointense lesion load · patients with relapsing‐remitting multiple sclerosis
1 finding from 1 review
Intervention not reported
Intervention (no. of studies/participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found